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E-mail: didier.raoult@gmail.comThe publication of guidelines promoted by the European Soci-
ety of Clinical Microbiology and Infectious Diseases (ESCMID)
is under discussion in ESCMID and CMI.
Recently the usefulness of society-generated guidelines was
questioned in two papers stating that most guidelines are
neither read nor followed [1,2]. The duplication of guidelines
where one society repeats what another society has recently
published is another problem. Conﬂicting guidelines may be
observed as previously reported in this journal [3]. ESCMID
policy on commissioning and managing guidelines, on conﬂicts
of interest and on how chairpersons and members of guidelines
writing groups should be selected, are under discussion and
reconstruction. It is obvious from recent publications that
without such a policy, the validity of guidelines will be ques-
tioned. The Guidelines Editor and the Editor of the publishing
journal will have important roles in guarding against the publi-
cation of guidelines where the conﬂicts of interest among au-
thors were not properly managed [1–3] (see also: International
Committee of Medical Journal Editors, www.icmje.org/icmje-
recommendations.pdf; World Association of Medical Editors,
www.wame.org; and Committee on Publication Ethics, www.
publicationethics.org).
The recent development of the Cochrane library suggests
that for common diseases, with large published series, meta-
analysis may be as good as expert opinion. The latter is
indeed ranked at a lower level in evidence-based medicine,
although for rare diseases that may not be true [4].
A problem with experts on new compounds is that they
often have relationships with the industry. A quote oftenClinical Microbiology and Infection © 2015 European Society of Cascribed to Nobel prize winner Milton Friedman (but in reality
coined much earlier), ‘there is no such thing as a free lunch’,
implies that any such involvement, ﬁnancial or other, generates
loyalty and dependency [5].
While standing in line for a free coffee offered by industry at
an ICAAC meeting, many of us have seen a sign saying, ‘If you
are from Vermont, please step out of the line’. Among col-
leagues, this is often quoted as a silly and exaggerated level of
concern. However, it is not always easy to deﬁne the right level.
‘Conﬂicts of interest’ among experts in guidelines writing
groups need to be discussed within European societies. A
recent review of 14 guidelines from specialized societies found
that conﬂicts of interest were very common and often not
reported [1]. In France the scandal surrounding ‘Mediator’ [6],
illustrates that neglecting this basic principle may have dire
consequences. The rules on conﬂicts of interest in the Infec-
tious Diseases Society of America (IDSA) handbook for clinical
practice guideline development [7] can serve as a basis for such
a discussion. The chairperson of the writing group shall have no
current or recent conﬂict of interest directly related to the task
at hand. Participation in the guideline development process will
depend on an evaluation of ‘the disclosure of interests form’
that all prospective experts must complete. The IDSA deﬁnition
of conﬂict of interest includes relationships involving employ-
ment, consultancies, honoraria, stock ownership or options,
grants received and pending, patents received and pending,
royalties, and more. The IDSA makes a clear distinction be-
tween relationships related to research by the research arm of
the company, which may be accepted, and relationships related
to marketing, which are not allowed.
Both CMI and ESCMID encourage a discussion among col-
leagues on (i) the usefulness of guidelines, (ii) the format of a
useful guideline, (iii) the appointment of writing group chair-
persons devoid of conﬂicts of interest related to the job at
hand, (iv) the selection and exclusion of experts following
proper declarations of conﬂicts of interest and (v) theClin Microbiol Infect 2015; 21: 1043–1044
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1044 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIintroduction of a period of public consultation (as used by
EUCAST for many years) of guidelines before ﬁnalizing the
recommendations. During the period of public consultation,
recommendations can be questioned and each question can
receive a rebuttal or an explanation from the guidelines writing
group.
We will be attentive to the recommendations of the Inter-
national Committee of Medical Journal Editors (http://www.
icmje.org/icmje-recommendations.pdf), the World Association
of Medical Editors (www.wame.org), and the Committee on
Publication Ethics (www.publicationethics.org) on how to
handle declarations of conﬂicts of interest from authors. This is
even more important among guidelines authors because guide-
lines are meant to represent ‘a summary of all our current
knowledge and to present the truth as we know it and to
recommend diagnostic or therapeutic algorithms’. We cannot
hope that the situation is saved by the disturbing fact that
guidelines are neither read nor adhered to by our colleagues [1].
CMI is happy to publish useful guidelines based on science
and where the conﬂicts of interest of authors have been
reviewed and accepted by a chairperson devoid of any conﬂicts.
Authors with current conﬂicts recuse themselves by declining
invitations to take part and authors who have accepted to beClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectpart of the process must understand that they must decline new
conﬂicts of interest during the process.
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